Innovative pharmaceutical companies receive intensive research from institutions

36Kr
2025.10.09 23:31

Wind data shows that as of October 9, over 170 listed companies in the pharmaceutical and biotechnology industry have undergone institutional research since September. Notably, several innovative pharmaceutical companies, such as Mabwell and Gan & Lee, have received significant attention from institutions. Among the key topics of interest for institutions are R&D investment in innovative drug pipelines, R&D progress, and BD (business development) transactions. Institutions have stated that the industry trend of "innovation + internationalization" will remain unchanged, and they continue to be optimistic about the main line of innovative drugs. It is expected that the upcoming clinical data disclosures and BD transactions related to the European Society for Medical Oncology (ESMO) conference in 2025 will bring new investment opportunities to the sector. (China Securities Journal)

Source: 36Kr The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer